Wildfires can be worsened when a nearby storm fans their flames with its strong winds. Impact on property and human life
Tropical cyclones regularly affect the coastlines of most of Earths major bodies of water along the Atlantic, Pacific, and Indian oceans. Tropical cyclones have caused significant destruction and loss of human life, resulting in about 2 million deaths since the 19th century. Large areas of standing water caused by flooding lead to infection, as well as contributing to mosquito-borne illnesses. Crowded evacuees in shelters increase the risk of disease propagation. Tropical cyclones significantly interrupt infrastructure, leading to power outages, bridge and road destruction, and the hampering of reconstruction efforts. Winds and water from storms can damage or destroy homes, buildings, and other manmade structures. Tropical cyclones destroy agriculture, kill livestock, and prevent access to marketplaces for both buyers and sellers; both of these result in financial losses. Powerful cyclones that make landfall – moving from the ocean to over land – are some of the most impactful, although that is not always the case. An average of 86 tropical cyclones of tropical storm intensity form annually worldwide, with 47 reaching hurricane or typhoon strength, and 20 becoming intense tropical cyclones, super typhoons, or major hurricanes (at least of Category 3 intensity).In Africa, tropical cyclones can originate from tropical waves generated over the Sahara Desert, or otherwise strike the Horn of Africa and Southern Africa.
Telotristat ethyl (USAN, brand name Xermelo) is a prodrug of telotristat, which is an inhibitor of tryptophan hydroxylase. It is formulated as telotristat etiprate — a hippurate salt of telotristat ethyl.On February 28, 2017, the U.S. Food and Drug Administration (FDA) approved telotristat ethyl in combination with somatostatin analog (SSA) therapy for the treatment of adults with diarrhea associated with carcinoid syndrome that SSA therapy alone has inadequately controlled. Telotristat ethyl was approved for use in the European Union in September 2017.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Pharmacology
Telotristat is an inhibitor of tryptophan hydroxylase, which mediates the rate-limiting step in serotonin biosynthesis. Adverse effects
Common adverse effects noted in clinical trials include nausea, headache, elevated liver enzymes, depression, accumulation of fluid causing swelling (peripheral edema), flatulence, decreased appetite, and fever. Constipation is also common, and may be serious or life-threatening (especially in overdose). Formulations
It is marketed by Lexicon Pharmaceuticals (as telotristat etiprate). 328 mg telotristat etiprate is equivalent to 250 mg telotristate ethyl. References
Further reading
Kulke MH, ODorisio T, Phan A, Bergsland E, Law L, Banks P,  et al. (October 2014). "Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide". Endocrine-Related Cancer. 21 (5): 705–14. doi:10.1530/ERC-14-0173. PMC 4295770. PMID 25012985. External links
"Telotristat ethyl". Drug Information Portal. U.S. National Library of Medicine. "Telotristat etiprate". Drug Information Portal. U.S. National Library of Medicine.